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1. Introduction 
The normal physiology of the female reproductive system involves a hypothalamus that 
secretes gonadotropin-releasing hormone (GnRH)in a pulsatile manner, a pituitary gland 
that can be stimulated by the hypothalamus to regularly secrete both luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH), an ovary that has both methodical enzymatic 
system and steroidogenesis for producing the sex hormones such as estrogen and 
progesteron, and a functional uterus that can be responded by these hormones.  
Sex hormones play a crucial role in reproductive biology as well as in general physiology. 
The most important aim of sex hormones is to design the cycle and to produce an optimal 
environment for pregnancy according to form ovarian physiology including follicular 
growth, ovulation, and corpus luteum formation and endometrial response including 
proliferative and secretuar phase for implantation. Among the various functions, sex 
hormones influence pregnancy, cardiovascular function, bone metabolism, and an 
individual's sense of general well-being. The action of sex hormones is mediated via 
extracellular signals to the nucleus to affect a physiologic response. 
2. Gonadotropin-releasing hormone (GnRH) 
Gonadotropin-releasing hormone (GnRH) is a decapeptide pulsatile produced by neurons 
with cell bodies primarily in the arcuate nucleus of the hypothalamus (1). Embryologically, 
these neurons originate from the olfactory area and then migrate to their adult locations (2). 
These GnRH-secreting neurons project axons that terminate on the portal vessels at the 
median eminence where GnRH is secreted for delivery to the anterior pituitary. The 
continual pulsatile secretion of GnRH is necessary because its short half-life is only 2–4 
minutes as a result of rapid proteolytic cleavage. 
GnRH stimulates the production, secretion and storage of FSH and LH from anterior 
hypophysis. (3). It is also an unique releasing hormone for the regulation of the 
simultaneous secretion of two hormones in human body (4). GnRH performs this special 
affect according to its pulsatile secretion. In the follicular phase, its secretion is characterized 
by frequent, small-amplitude pulses, however during the luteal phase, there is a progressive 
lengthening of the interval between pulses with higher amplitude (5). 
GnRH is primarily involved in endocrine regulation of gonadotropin secretion from the 
pituitary. However, the regulation of GnRH secretion is various (Table 1). The pulsatile 
secretion of GnRH is directly affected by catecholaminergic system including the activator of  
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Inhibitors of GnRH secretion Activators of GnRH secretion 
Dopamine Norepinephrin 
Gonadotrophins (negative feedback) Catecholamins 
Endogenous opioids Neuropeptide Y 
Estradiol  Acetylcholine 
Progesterone VIP 
CRH Naloxone 
Melatonin  
Serotonin  
GABA  
Table 1. The control of GnRH secretion 
norepinephrine and the inhibitor of dopamin. This system is basically regulated by 
endogenous opioids (6). 
These opioids are three groups; 
1. Endorphins 
2. Enkephalins 
3. Dynorphins 
Endogenous opioids, inhibit the gonadotropin secretion to swage the GnRH secretion from 
hypothalamus. 
Sex steroids affect GnRH by increasing the secretion of the endogenous opioids in the 
central nervous system (7). 
Although estrogen stimulates the secretion of endogenous opioids, estrogen plus 
progesterone increase this effect. Clinically, increased endogenous opioids may cause 
hypothalamic amenorrhea.   
3. GnRH analogs 
3.1 GnRH agonists (leuprolide, goserelin, nafarelin, buserelin) 
GnRH agonists are modifications of the native molecule to either increase receptor affinity 
or decrease degradation (8). The pulsatile usage of GnRH agonists that resemble 
endogenous GnRH leads to increase the secretion of FSH and LH. However the constant 
GnRH usage leads to suppression of gonadotropin secretion by the downregulation of its 
receptor. An initial release of gonadotropins is followed by a profound suppression of 
secretion. The initial release of gonadotropins represents the secretion of pituitary stores in 
response to receptor binding and activation. With continued activation of the gonadotroph 
GnRH receptor, however, there is a downregulation effect and a decrease in the 
concentration of GnRH receptors. As a result, gonadotropin secretion decreases and sex 
steroid production falls to castrate levels (9). 
The most commonly used regimen for superovulation in ART is called the long, or luteal, 
downregulation protocol. In this protocol, GnRH agonist is started in the luteal phase (day 21) 
of the previous cycle, which minimizes its flare effect and prevents the follicular recruitment 
that is thought to begin in the luteal phase. The couple undergoing treatment is advised to 
abstain from intercourse during the cycle before the start of COH; however, concomitant use 
of GnRH agonist in the presence of an unsuspected pregnancy has not been reported to be 
associated with increased spontaneous abortion, congenital abnormalities, or pregnancy 
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complications. Most importantly, clinical pregnancy rates and live birth rates per retrieval 
were significantly higher using the long protocol. The benefits including higher pregnancy 
rates and lower OHSS rates of using the long protocol for administration of GnRH agonists 
greatly outweigh its disadvantages, which include daily administration, increased 
requirement for gonadotropins, and an overall increase in the cost of medication (10, 11). 
3.2 GnRH antagonists (cetrorelix, ganirelix) 
GnRH antagonists produce a competitive blockage of GnRH receptors, preventing 
stimulation by endogenous GnRH and causing an immediate fall in gonadotropin and sex 
steroid secretion. The clinical effect is generally observed within 24 to 72 hours. Moreover, 
antagonists may not show flare-up affect comparing with GnRH agonists. GnRH 
antagonists are also used in ART for the prevention of premature ovulation and displays 
similar efficacy comparing GnRH agonist (long protocol) (12). However, there were 
significantly fewer pregnancies with the GnRH antagonist protocol. A significant reduction 
in the incidence of severe OHSS and the number of gonadotropin injections were observed 
in the antagonist regimen compared with the long GnRH–agonist protocol. 
When we searched the Cochrane Library and ACOG Commitee on Practice Bulletins.;  
Clinically usage of GnRH analogs listed below; 
- Endometriosis 
- Hormon dependent neoplasia such as endometrium cancer, breast cancer. 
- Myomas of uterus 
- Precocious puberty 
- Dysfunctional uterine bleeding 
- Ovarian hyperandrogenism 
- Premenstrual syndrome 
- ART for control of premature ovulation 
Side effects of GnRH analogs listed below; 
- Hypoestrogenic state 
- Vasomotor symptoms 
- Vaginal dryness 
- Mood changes 
- Loss of bone mineral density 
Usage of these agents is generally limited to 6 months because of the adverse effects as listed 
above. The most important side effect is osteoporosis. Many side effects can be minimized 
by providing add-back therapy in addition to the agents.The addition of 2.5 mg of 
norethindrone or 0.625 mg of conjugated estrogens with 5 mg/d of medroxyprogesterone 
acetate seems to relieve these side effects of GnRH analogs. The addition of 5 mg daily of 
norethindrone acetate alone or in conjunction with low-dose conjugated equine estrogen 
seems to eliminate the loss of bone mineral density effectively as well (13). 
4. Gonadotropins 
The gonadotropins FSH and LH are produced by the anterior pituitary gonadotroph cells 
and are responsible for ovarian follicular stimulation. Structurally, there is great similarity 
between FSH and LH. They are both glycoproteins that share identical ┙ subunits and differ 
only in the structure of their ┚ subunits, which confer receptor specificity (14). The synthesis 
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of the ┚ subunits is the rate-regulating step in gonadotropin biosynthesis (Lalloz MRA, et al. 
GnRH desensitization preferentially inhibits expression of the LH ┚-subunit gene in vivo. 
Endocrinology 1988;122:1689–1694.). Thyroid-stimulating hormone and placental human 
chorionic gonadotropin (hCG) also share identical ┙ subunits with the gonadotropins. The 
structural similarity between FSH, LH, TSH and hCG defines as the ┙ subunits identical and 
the ┚ subunits differ. 
The gonadotropins were metabolized in liver and kidney then excreted by the way of urine. 
The half life of LH, FSH and hCG is 20 minute, 3-4 hours and 24-36 hours, respectively. 
4.1 FSH  
Receptors of FSH are found on granulosa cells.  
FSH plays role in; granulosa cell proliferation in follicules and estrogen production   
- the production of FSH and LH receptors on granulosa cells 
- the activation of aromatase and 3 beta-hydroxysteroid dehydogenase                  
- enzymes 
- the stimulation of follicules and prevention of apoptosis of them 
In the beginning of follicular development, there is no LH receptor on granulosa cells, 
however, during the 11-12nd days of cycle, FSH stimulates the production of LH receptors 
on granulosa cells. 
4.2 LH 
Receptors of LH are found on theca cells.  
LH plays role in; internal thecal cell proliferation in follicules and androgen production   
- luteinization and the production of progesterone when LH receptors found on 
- granulosa cells during the 11-12nd days of cycle 
- providing of ovulation 
- the completion of I. myosis (the transformation of primary oocyte to  
- secondary oocyte) 
Although FSH plays an important role for the early maturation of follicules, FSH and LH are 
responsible together for the maturation of follicules before the ovulation. 
5. Inhibin 
Inhibin secretes from granulosa cells, sertoli cells, placenta and the basophilic cells of 
hypophysis. In the cycle, Inhibin selectively inhibits the secretion of FSH. There are two 
forms; Inhibin A and Inhibin B. The affect of Inhibin B mostly shows on follicular phase, but 
the affect of Inhibin A mostly shows on luteal phase of cycle. During luteofollicular 
transition of cycle FSH increase by decreasing of Inhibin A levels. Inhibin also stimulates LH 
activity and IGF secretion from granulosa and theca cells to increase androgen production. 
6. Activin 
Activin secretes from granulosa cells and the basophilic cells of hypophysis. In the cycle, 
Activin selectively activates the secretion of FSH. Therefore, it activates all affects of FSH on 
granulosa cells. Activin also inhibits LH activity, androgen production from theca cells and 
progesterone production from granulosa cells. Additionally, activin inhibits the secretion of 
IGF from ovary and the secretion of prolactin, ACTH, and GH from hypophysis. These 
www.intechopen.com
 
Sex Hormones and Infertility 
 
85 
affects of activin is inhibited by inhibin and follistatin. Follistatin that secretes from 
granulosa cells and the basophilic cells of hypophysis inhibits FSH activity by binding 
activin. 
6.1 IGF 
IGF secretes from granulosa cells and theca cells. Its affect is similar to GH.  
IGF plays role in; the stimulation of LH activity on theca cells to increase androgen 
production 
- the production of FSH and LH receptors on granulosa cells 
- the activation of aromatase enzyme 
- the proliferation of granulosa cells 
-  the improvement of progesterone synthesis 
All of IGF binds insulin like growth factor binding protein (IGF-BP) in the circulation. FSH 
and insulin inhibit the synthesis of IGF-BP, so efficacy of IGF may increase by increasing 
free IGF.  
Epidermal growth factor (EGF) that is an important inhibitor of FSH in the ovary is another 
growth factor. 
7. Steroid hormones in reproduction 
Sex steroid hormones are synthesized in the gonads, adrenal gland, and placenta. Cholesterol 
is the primary building block in steroidogenesis, and all steroid-producing tissues except the 
placenta are capable of synthesizing cholesterol from the 2-carbon precursor, acetate. Steroid 
hormone production, which involves at least 17 enzymes, primarily occurs in the abundant 
smooth endoplasmic reticulum found in steroidogenic cells. 
Steroids are metabolized mainly in the liver and to a lesser extent in the kidney and 
intestinal mucosa. Accordingly, administration of certain pharmacologic steroid hormones 
may be contraindicated in those with active liver disease. Sex steroids are divided into three 
groups based on the number of carbon atoms that they contain. Each carbon in this structure 
is assigned a number identifier, and each ring is assigned a letter. The 21-carbon series 
includes progestins as well as glucocorticoids and mineralocorticoids. Androgens contain 19 
carbons, whereas estrogens have 18. However the ovary is deficient in 21-hydroxylase and 
11 -hydroxylase and therefore is unable to produce corticosteroids. Most important 
steroidogenic enzymes are listed in Table 2. Steroidogenesis is summarized in Figure 1.  
 
Enzyme Cellular  Location Reactions 
P450scc  
 
Mitochondria Cholesterol side chain 
cleavage 
P450c11  
 
Mitochondria 11-Hydroxylase  
18-Hydroxylase 
19-Methyloxidase 
P450c17  Endoplasmic reticulum 17-Hydroxylase 
17, 20-Lyase 
P450c21  Endoplasmic reticulum 21-Hydroxylase 
P450arom  Endoplasmic reticulum Aromatase 
Table 2. Steroidogenic enzymes  
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Fig. 1. The steps of the steroidogenesis pathway 
Most steroids in the peripheral circulation are bound to carrier proteins, either specific 
proteins such as sex-hormone binding globulin (SHBG) or corticosteroid-binding globulin, 
or to nonspecific proteins such as albumin. Only 1 to 2 percent of androgens and estrogens 
are unbound or free. Tablo 3 shows the steroid transformations. Levels of SHBG are 
increased by hyperthyroidism, pregnancy, and estrogen administration. In contrast, 
androgens, progestins, GH, insulin, and corticoids decrease SHBG levels. 
8. Estrogens 
Steroids with 18 C classified as; 
Estron (E1): Poor estrogenic affect, basically peripheric estrogen are the properties. It is 
dominant estrogen in prepubertal and postmenopausal periods. 
Estradiol (E2): The most potent estrogen is mainly produced in the reproductive age. 
Estratriol (E3):  The least potent estrogen is mainly produced in pregnancy and synthesized 
by maternal and fetal units together. Therefore, E3 is an indicator to show the normal 
fetoplacental unit. 
Estetrol (E4): There is not estrogenic affect. It is synthesized from fetal liver and increases in 
term. 
Estrogens are produces by the aromatization of androstenedione and testosterone in ovary 
and the peripheral aromatization of androstenedione in skin, fat tissue, muscle and 
endometrium (Figure 2). There is a two-cell theory of ovarian steroidogenesis. The two-cell 
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theory of ovarian steroidogenesis explains that estrogen biosynthesis requires the combined 
action of two gonadotropins (LH and FSH) on two cell types (theca and granulosa cells) (15). 
Until the late antral stage of follicular development, LH-receptor expression is limited to the 
thecal compartment and FSH-receptor expression is limited to the granulosa cells. Theca 
cells express all of the genes needed to produce androstenedione. This includes high levels 
of CYP17 gene expression, whose enzyme product catalyzes 17-hydroxylationation the rate-
limiting step in the conversion of progesterones to androgens (16). This enzyme is absent in 
the granulosa cells, so they are incapable of producing the precursor needed to produce 
estrogens by themselves. Granulosa cells therefore rely on the theca cells as their primary 
source for estrogen precursors. In response to LH stimulation, theca cells synthesize the 
androgens, androstenedione and testosterone. These androgens are secreted into the 
extracellular fluid and diffuse across the basement membrane to the granulosa cells to 
provide precursors for estrogen production. In contrast to theca cells, granulosa cells express 
high levels of aromatase activity in response to FSH stimulation. Thus, these cells efficiently 
convert androgens to estrogens, primarily the potent estrogen, estradiol. In sum, ovarian 
steroidogenesis is dependent on the effects of LH and FSH acting independently on the 
theca cells and granulosa cells, respectively.  
 
 
Fig. 2. Estrogen biosynthesis 
Estrogen is metabolized in liver and excreted to bile. 
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The effects of estrogen on; 
Genitourinary system: 
 Stimulation of urethral epithelial proliferation 
 Stimulation of vaginal epithelial proliferation and superficial cells of epithelium may 
become dominant in vagina. 
 Decreases the vaginal pH (3.8-4.5) 
 Increases the cervical mucus and elasticity and decreases the cervical viscosity (Spinn-
Barkeit) 
 Increases the crystallization of NaCl in cervical mucus and may cause ferning image. 
 Increase cervical mucus pH 
 Proliferation of endometrial stroma and glands 
 Production of endometrial progesterone receptor 
 Increase the gap junctions, connexion proteins, and oxytocin sensitivity of smooth 
muscles in uterus. Therefore, estrogen increases the uterin contractility. 
 Increase the ciliary activity and motility in fallopian tubes 
 Facilitate follicular stimulation 
 Inhibits FSH (negative feed-back effect) 
 Positive feed-back on LH before the ovulation 
 Inhibits GnRH (Increase central opioids) 
Breast 
 Development of ductus 
Seconder sex characters 
 Development of axillary and pubic hairs in puberty (pubarche) 
 Development of breast in puberty (thelarche) 
Bone 
 Increase the osteoblastic activity in bone and bone mineral density 
Skin 
 Increase vascularity and collagen 
Liver 
 Increase SHBG synthesis 
 Increase transcortin synthesis 
 Increase angiotensinogen 
 Increase coagulation factors as Factor II, VII, VIII, IX, and X 
 Decrease antithrombin production 
 Increase triglycerides, total cholesterol, and HDL 
 Decrease LDL 
 Increase concentration of bile acids and the development of cholelithiasis 
Estrogens exert a variety of effects on growth and development of different tissues. The 
effects of estrogens are mediated via estrogen receptors (ER), intracellular proteins that 
function as ligand-activated transcription factors and belong to the nuclear receptor 
superfamily. Two mammalian ERs have been identified, denoted ER┙ and ER┚. The 
structure of both receptors is similar and consists of six domains named A through F from 
the N- to C-terminus, encoded by 8 to 9 exons. Genes that are regulated by activated ERs 
include early gene responses such as c-myc, c-fos, and d-jun, as well as genes encoding for 
growth factors such as insulin growth factor (IGF-1 and IGF-2), epidermal growth factor 
(EGF), transforming growth factor-┙, and colony-stimulating factor (CSF-1). 
In addition to the described genomic effects of estrogens, there is growing evidence for 
nongenomic effects of estrogens on intracellular signal transduction pathways. These effects 
www.intechopen.com
 
Sex Hormones and Infertility 
 
89 
include, for example, rapid activation of the adenylate cyclase, which results in cyclic 
adenosine monophosphate (cAMP)–dependent activation of protein kinase A (PKA). 
Estrogens can also stimulate the mitogen-activated protein kinase (MAPK) pathways and 
rapidly activate the Erk1/Erk2 proteins (17). 
 
 Free Albumin SHBG Transcortin 
Estrogen % 1 % 30 % 69 - 
Testosterone % 1-2 % 20-32 % 66-78 - 
DHEA % 4 % 88 % 8 - 
Androstenedione % 7 % 85 % 8 - 
DHT % 1 % 71 % 28 - 
Progesterone % 2 % 80 % 1> % 18 
Cortisol % 10 % 15 - % 75 
Table 3. Steroid transformations 
The combined production of estradiol and inhibin B by the dominant follicle results in the 
decline of follicular phase FSH levels, and at least in part, may be responsible for the failure 
of other follicles to reach preovulatory status during any one cycle. This model predicts that 
follicles that lack adequate FSH receptor and granulosa cell number will remain primarily 
androgenic and will therefore become atretic. In support of this model, an increased 
androgen:estrogen ratio is found in the follicular fluid of atretic follicles and a number of 
studies have demonstrated that high estrogen levels prevent apoptosis. IGF also has 
apoptosis-suppressing activity, and is produced by granulosa cells. This action of IGF-I is 
suppressed by certain IGF-binding proteins that are present in the follicular fluid of atretic 
follicles. The action of FSH to prevent atresia may therefore result, in part, from its ability to 
stimulate IGF-I synthesis and suppress the synthesis of the IGF-binding proteins. 
Clinically, there are some selective estrogen receptor modulators (SERM) such as 
clomiphene citrate (CC), tamoxifen, and raloxifen (Table 4). 
 
 Breast Genital Kemik Lipid 
Clomiphene citrate + _ + + 
Tamoxifen,  _ + + + 
Raloxifen _ _ + + 
Table 4. The effects of selective estrogen receptor modulators on some tissues 
CC is the initial treatment for most anovulatory infertile women. Chemically similar to 
tamoxifen, CC is a nonsteroidal triphenylethylene derivative that demonstrates both 
estrogen agonist and antagonist properties. Antagonist properties predominate except at 
very low estrogen levels. As a result, negative feedback that is normally produced by 
estrogen in the hypothalamus is reduced. Gonadotropin-releasing hormone (GnRH) 
secretion is improved and stimulates pituitary gonadotropin release. The resulting increase 
in follicle-stimulating hormone (FSH), in turn, drives ovarian follicular activity. 
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The SERM tamoxifen is an estrogen antagonist in the breast that is used in the treatment of 
estrogen-receptor positive breast cancer. Tamoxifen (20 mg) also has been approved for the 
prevention of breast cancer in high-risk women, resulting in an approximately 50% 
reduction in the risk of disease (18).  
Raloxifene is a SERM that has been approved for both the prevention and treatment of 
osteoporosis. Raloxifene exercises estrogen-like actions on bone and lipids without 
stimulating the breast or endometrium. Raloxifene also may reduce the risk of breast cancer. 
Postmenopausal women receiving raloxifene as part of a large osteoporosis treatment trial 
experienced a 76% reduction in the risk of invasive breast cancer compared with placebo-
treated women (19). 
 
Androgens Potence Ovary Adrenal Peripheral 
DHEA _ % 25 % 50 % 25 
DHEAS 5 _ % 100 _ 
Androstenedione 10 % 50 % 50 _ 
Testosterone 100 % 25 % 25 % 50 
DHT 300 _ _ % 100 
Table 5. Androgen biosynthesis 
9. Progesterone 
Progesterone is the 21 C steroid that secretes mainly from corpus luteum and placenta. It 
minimally secretes from the cortex of adrenal gland. Although its level is 1 ng/mL in 
preovulatuary phase, it is 3-15 ng/mL in luteal phase. Also, progesterone has a thermogenic 
affect. 
The effects of progesterone on; 
Genitourinary system: 
 Intermediate cells of epithelium may become dominant in vagina. 
 Increases the vaginal pH (> 4.5) 
 Increases the cervical viscosity and decreases the cervical mucus and elasticity  
 Decreases cervical mucus pH 
 Antiproliferative and antimitotic effects on endometrial stroma and glands 
 Secretuar changes on endometrium for implantation 
 Decraeses the gap junctions, connexion proteins, and oxytocin sensitivity of smooth 
muscles in uterus. Therefore, progesterone decreases the uterin contractility 
 Decrease the ciliary activity and motility in fallopian tubes 
 Antiestrogenic activity according to the decrease in estrogen receptor and the increase 
in transformation of E2 to E1 (stimulates 17 OHSD enzyme) 
 Inhibits LH (negative feed-back effect) 
 Positive feed-back on FSH before the ovulation 
 Inhibits GnRH (Increase central opioids) 
Breast 
 Development of alveols and lobules  
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Bone 
 Antiresorptive effects on bone and increase bone mineral density 
Liver 
 Decrease SHBG synthesis 
Most progesterone actions on the female reproductive tract are mediated through nuclear 
hormone receptors. Progesterone enters cells by diffusion and in responsive tissues becomes 
associated with progesterone receptors (Conneely OM, et al: Reproductive functions of 
progesterone receptors. Recent Prog Horm Res 57:339, 2002). There are multiple isoforms of 
the human progesterone receptor. The best understood isoforms are the progesterone 
receptor type A (PR-A) and B (PR-B). Both arise from a single gene, are members of the 
steroid receptor superfamily of transcription factors, and regulate transcription of target 
genes. These receptors have unique actions. When PR-A and PR-B receptors are co-
expressed, it appears that PR-A can inhibit PR-B gene regulation. The inhibitory effect of PR-
A may extend to actions on other steroid receptors, including estrogen receptors. 
10. Androgens 
The ovary produces primarily androstenedione and dehydroepiandrosterone (DHEA) with 
small amounts of testosterone. Although the adrenal cortex primarily produces 
mineralocorticoids and glucocorticoids, it also contributes to approximately one-half of the 
daily production of androstenedione, DHEA, and essentially all of the sulfated form of 
DHEA (DHEAS). Twenty-five percent of circulating testosterone is secreted by the ovary, 25 
percent is secreted by the adrenal gland, and the remaining 50 percent is produced by 
peripheral conversion of androstenedione to testosterone (Figure 3). 
11. Anti-Müllerian hormone (AMH) 
AMH has been identified as a dimeric glycoprotein and a member of the transforming 
growth factor beta (TGFb) family of growth and differentiation factors. The pool of 
primordial follicles in the ovary is related to the number of growing antral follicles. Antral 
follicles are responsive to gonadotrophin stimulation and the measure of ovarian reserve 
can be defined as the total number of follicles, which can be stimulated to grow under 
maximal stimulation. Classically, age, FSH levels in the early follicular phase, antral follicle 
count and inhibin B have been used as markers of ovarian reserve. More recently, AMH, 
have been used by various groups to assess the ovarian reserve (20). 
AMH is initially expressed in ovarian granulosa cells of primary follicles, maximal 
expression occurs in pre-antral and small antral follicles. Antral follicles measuring <6 mm 
express the greatest amount of AMH, and that expression declines as antral follicles increase 
in size. AMH is not expressed by atretic follicles and during FSH dependent final stages of 
follicular growth. AMH inhibits initial primordial follicles recruitment and decreases the 
sensitivity of preantral and small antral follicles to FSH. Serum AMH concentrations decline 
with increasing age and constitute a sensitive marker for ovarian aging. Recently, AMH is 
used as pretreatment assessment of ovarian reserve.  
Basal serum levels of AMH may more accurately reflect the total developing follicular 
cohort and consequently potential ovarian response to FSH in cycles of ART. AMH, antral 
follicle count, inhibin B, FSH and ovarian volume have been demonstrated to reflect ovarian 
reserve. 
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12. Infertility 
Infertility is defined as 1 year of unprotected intercourse without pregnancy. This condition 
may be further classified as primary infertility, in which no previous pregnancies have 
occurred, and secondary infertility, in which a prior pregnancy, although not necessarily a 
live birth, has occurred. Infertility affects about 10% to 15% of reproductive age couples.  
(21). Various factors may be responsible for the inability to achieve a successful pregnancy. 
Ovulatory, anatomic, immunologic, or hormonal factors on the woman's side and 
abnormalities of the semen parameters on the man's side are the most common (Table 6). 
After a thorough work-up, treatment can be planned that aims to correct the problem 
identified or, in the case of unexplained infertility, tries to improve all steps of the 
reproductive process. 
 
 Prevalence of the etiologies of infertility (%)  
Male factor  25–40 
Female factor  
-  Ovulatory dysfunction  
- Tubal or periotoneal factor  
- Unexplained infertility  
- Miscellaneous causes  
40–55 
30–40 
30–40 
10–15 
10–15 
Both male and female factors  10 
Unexplained infertility  10 
Table 6. Causes of Infertility 
13. Evaluation of infertility 
The most important tests for evaluation of infertility are to assess the ovarian function.  
13.1 Ovarian function 
Ovarian function can be evaluated by various methods. Regular menstrual cycles are a sign 
of ovulation in 95% of the cycles. Because the ovaries also "age," however, the regularity of 
the cycles alone is not enough to characterize ovarian function. The number of follicles in the 
ovaries decreases from birth. As a result, from the age of 30 onward a slow decline in 
fertility occurs. This decline parallels the reduction in the number and quality of the follicles 
and oocytes. The first sign of reduced ovarian activity is the shortening of the follicular 
phase, which reduces the length of the ovulatory cycle. The decrease in the number of 
follicles is followed by hormonal changes. Inhibin B is produced by the small antral follicles, 
and as their number declines, the ovarian output of inhibin B decreases. This is paralleled by 
a rise in FSH level. 
For the everyday practice, there are several tests to assess ovarian reserve. Measurement of 
the early follicular phase FSH and estradiol levels to determine the FSH/estradiol ratio; 
measurement of inhibin B or anti-Müllerian hormone levels; or the early follicular phase 
antral follicle count are options (Table 7). Dynamic tests evaluate the ovaries during 
clomiphene citrate (CC) challenge or during gonadotropin-releasing hormone agonist 
(GnRHa) or gonadotropin stimulation.   
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Test Normal Value Abnormal Value 
Cycle Day 3 FSH < 10-15 mIU/mL > 10-15 mIU/mL 
Cycle Day 3 
estradiol 
< 80 pg/mL > 80 pg/mL 
Inhibin B > 45 pg/mL < 45 pg/mL 
Anti-Müllerian 
hormone 
> 2.7 ng/mL associated with improved 
oocyte quality as reflected in a higher 
implantation rate and trend toward better 
clinical pregnancy rate[56] 
Low levels 
Clomiphene citrate 
challenge test 
FSH < 26 mIU/mL on Day 10 
FSH > 26 mIU/mL 
on Day 10 
Gonadotropin 
stimulation test 
Estradiol level elevation and subsequent 
decrease 
No elevation of 
estradiol level 
Antral follicle count 
on ultrasound 
> 3-4 < 3-4 
Ovarian volume on 
ultrasound 
> 3 mL < 3 mL 
*Note: Different infertility centers use different tests. Cut-off values may differ from center to center on 
the basis of their experience and results. 
Table 7. Cut-off Values* for the Most Commonly Used Ovarian Reserve Tests 
On the one hand, the results of these tests will help with designing treatment (to choose the 
appropriate treatment, stimulation protocol, and gonadotropin dose), and on the other hand 
they will be useful for counseling the couple. It is very important that a couple undergoing 
any form of assisted reproduction has realistic expectations (22).  
In addition to these tests, it is useful to perform an ultrasound midcycle to assess the ovary 
and uterus and to document ovulation. Midcycle ultrasound will document follicle growth 
and allow us to look at the endometrial lining (eg, thickness and type). Ovulation can be 
documented in several ways. The easiest is to measure a midluteal phase progesterone level. 
Changes in the basal body temperature, urinary LH kits, luteal phase endometrial biopsy, 
and serial ultrasounds are alternatives for assessing ovulation. 
When the cycles are irregular, other hormonal measurements -- such as testosterone, 
dehydroepiandrosterone sulfate (DHEAS), 17-OH progesterone, cortisol, prolactin -- as well 
as thyroid function tests and dynamic evaluation of pituitary function may be necessary for 
the infertility work-up. If the results of any of these tests are considered abnormal, 
conducting imaging studies (eg, MRI, CT, thyroid scan) may be the appropriate step. 
13.2 Ovulation induction, controlled ovarian hyperstimulation 
Ovulation induction has a role in the management of patients with anovulation/oligo-
ovulation or regular cycles. In the case of oligo-ovulation, the goal is to restore mono-
ovulatory cycles. 
Various drugs can be used to restore ovulation. Selective estrogen receptor modulators (eg, 
CC, tamoxifen) are usually administered first. CC is the agent for which most experience has 
accumulated. It is administered from Day 3 or 5 of the cycle for 5 days. The starting dose is 
50 mg, but if needed the dose can be increased by 50 mg daily during subsequent 
stimulation. Usually, a daily dose > 150 mg is not recommended, as higher doses compromise 
endometrial development, and pregnancy rates are very low. Ovulation rates are high (80%) 
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with CC, but cumulative pregnancy rates are only around 40%. The difference between the 
high ovulation rates and relatively low pregnancy rates is most likely due to the antiestrogenic 
effects of CC on the periphery, most prominently at the level of the endometrium. If 
pregnancy does not occur after a maximum of 6 cycles, other options need to be explored (23).  
CC stimulation can be combined with ovulation induction with human chorionic 
gonadotropin (hCG), especially when a spontaneous LH surge cannot be documented. The 
multifetal gestation rate is about 10% with CC use. CC has relatively few side effects, with 
gastrointestinal symptoms, visual changes, and hot flashes being more common. 
Aromatase inhibitors (eg, letrozole, anastrozole) have been explored recently. Aromatase is an 
enzyme that regulates the androgen-estrogen conversion. Aromatase inhibitors work by 
reducing estradiol level and therefore increasing pituitary gonadotropin output (resulting in 
decreased estradiol negative feedback). Their use is seldom associated with multifollicular 
development. Pregnancy rates are about 15% to 20 % per cycle. No adverse perinatal outcome 
following aromatase inhibitor use has yet been reported in the published, peer-reviewed 
literature, although the authors of a study presented during the American Society for 
Reproductive Medicine meeting in 2005 reported a higher rate of congenital anomalies with 5 
mg anastrozole (24, 25, 26). Notably, letrozole has warned clinicians against prescribing drugs 
for ovulation induction on the basis of reports of birth defects and spontaneous miscarriages in 
its safety database (27). Letrozole is not approved for ovulation induction. 
Insulin-sensitizing agents have been successfully used to treat infertile patients with PCOS. 
Metformin (1500 to 2000 mg daily) has been used most widely. With metformin, ovulation can 
be documented in about 50% to 60% of cases. Metformin can also be combined with CC in CC-
resistant cases. Lower miscarriage rates and fewer cases of gestational diabetes have been 
reported with metformin use. Metformin is a category B drug; no serious adverse effects have 
been reported with use during pregnancy. Gastrointestinal side effects are often reported upon 
initiation of treatment. It is a good approach to start with a lower daily dose and slowly increase 
it to the therapeutic range. Metformin should not be used in women with liver or renal disease. 
It takes at least 2 to 3 months for insulin sensitizers to take full effect (28, 29, 30, 31, 32).  
Gonadotropins can be administered when oral preparations are ineffective or do not lead to 
pregnancy after repeated attempts. Gonadotropins can be used alone or in combination with 
oral preparations and are usually started on Day 3 of the cycle at an initial dose of 75 to 150 IU. 
Cycle monitoring (ultrasound ± estradiol measurement) begins after 5 days of stimulation. 
When gonadotropins are combined with oral preparations, the pill is initiated first (usually on 
Day 3) and the injections are administered starting 2 days later. Injections are usually 
administered on every other day. These protocols can be adjusted depending on the response. 
Although pregnancy rates are higher following gonadotropin stimulation, the risks for 
multiple gestations and ovarian hyperstimulation syndrome (OHSS) are increased as well. 
Ovulation induction cycles can be completed in different ways. Urinary LH kits can be used 
to predict ovulation and to time intercourse or insemination. Alternatively, when the lead 
follicle is around 18 to 20 mm in diameter, human chorionic gonadotropin (hCG) can be 
administered to induce ovulation. When hCG is used, intercourse or insemination is 
scheduled 36 to 40 hrs after the injection. 
14. Intrauterine Insemination 
Intrauterine insemination (IUI) further improves the chances of pregnancy. IUI is more 
effective than intracervical or intravaginal insemination. Its use is especially indicated when 
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mild male factor or cervical factor infertility is diagnosed. A wide range of pregnancy rates 
have been reported after insemination (5% to 20% per cycle). Pregnancy rates are higher 
when gonadotropin stimulation is used in conjunction with IUI. Pregnancy rates are affected 
by the age of the female partner, semen parameters, tubal status, the presence of 
endometriosis, and the order of the treatment cycle. The pregnancy and multiple gestation 
rates are highest with the first treatment cycle. Some even recommend performing the first 
IUI in a natural unstimulated cycle to avoid multiple gestations and only to proceed with 
stimulation if the first attempt fails. Usually IUI should not be repeated more than 3 or 4 
times. Two exceptions are when donor sperm is used and when the patient has oligo-
ovulation; in these cases, a significant number of further pregnancies have been reported in 
a 5th or 6th cycle. The decision should be made individually, and the availability of IVF 
obviously influences the decision (33, 34).  
15. In vitro fertilization, intracytoplasmic sperm injection 
The first baby conceived after IVF treatment was born in 1978. Since then, the field has 
undergone enormous development, and IVF is now routinely used in the management of 
various forms of infertility. Initially, it was used for the treatment of tubal factor infertility, 
but today it is used to help patients with male factor infertility, unexplained infertility, 
genetic problems, and those who fail in vivo treatments. 
Early on, IVF was carried out during the patients' natural cycle. Later, CC was added to the 
protocol to increase efficacy. These cycles were characterized by relatively high cancellation 
rates as a result of premature ovulation and low pregnancy rates. With the advent of GnRH 
agonists, antagonists, and different types of gonadotropins, new stimulation protocols have 
been developed. Cycles with these protocols, by contrast, are characterized by very low 
cancellation rates, a higher number of oocytes, better-quality embryos, and significantly 
higher implantation and pregnancy rates. 
A typical IVF cycle is made up of 3 parts: stimulation, egg retrieval, and embryo transfer. 
Stimulation usually consists of pretreatment and stimulation. Pretreatment with oral 
contraceptive pills or a GnRH agonist allows flexible cycle scheduling and a more 
simultaneous follicle growth. In the various stimulation protocols, GnRH agonist or antagonist 
can be given to prevent premature LH surges. The GnRH agonist can be initiated in the luteal 
phase of the preceding cycle (long protocol) or with the onset of menstruation together with 
gonadotropins (short, ultrashort protocols). The GnRH agonist initially depletes the pituitary 
gonadotropin stores ("flare up" effect) before it prevents further FSH and LH release (usually 
after 7 to 12 days). This initial flare effect is used with the short protocols. 
A GnRH antagonist has a different mechanism of action. It competes with GnRH for its 
pituitary receptors. Upon administration it immediately prevents FSH and LH release. In 
GnRH antagonist cycles, the antagonist is administered either on Day 6 of stimulation (fixed 
protocol) or when the lead follicle reaches 14 mm in diameter (flexible protocol). 
There are 5 or 6 different stimulation protocols in use by IVF centers. Subtle differences in the 
management of the pretreatment phase or in the type and dose of gonadotropins do exist 
between IVF clinics. Several patient characteristics are considered before one decides about the 
protocol to be used. Typically, age, results of the ovarian reserve testing, and response to 
previous stimulation help with the decision about the appropriate stimulation protocol (35).  
Cycle monitoring (ultrasound and estradiol measurements) usually starts after 5 days of 
stimulation. When at least 2 follicles reach 17 to 18 mm in diameter, the final steps of oocyte 
maturation are induced by 5000 to 10,000 IU hCG. In those cycles during which GnRH 
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agonist downregulation is not applied, the final maturation of the oocytes can be induced 
with GnRH agonist as well. This method is associated with a lower incidence of OHSS. 
Oocyte retrieval is scheduled 35 to 36 hours after the final injection. 
Oocyte retrieval is an ultrasound-guided vaginal procedure that is performed under 
intravenous sedation. Oocytes are collected in culture medium and are processed for 
fertilization. Human tubular fluid was used as an example to design culture medium. 
Currently, several companies produce culture medium. Use of sequential media tries to 
satisfy the changing needs of the developing embryo. 
Fertilization may occur spontaneously when the sperm number, motility and morphology 
are within the normal range or can be done using intracytoplasmic sperm injection (ICSI). 
ICSI is used when the sperm parameters are suboptimal or when fertilization was poor in a 
previous cycle. During ICSI, the immobilized sperm is transferred through the zona 
pellucida with a fine glass needle to allow fertilization to take place (36).  
The day after the retrieval, the oocytes are checked for signs of fertilization (presence of 2 
pronuclei) and are cultured for an additional 2 to 4 days. Transfer usually takes place on Day 3 
or 5 after the retrieval. Embryos are assessed on the basis of blastomere number and 
morphology. Usually 2 or 3 good-quality embryos are transferred. The decision is influenced by 
the order of the cycle, the patient's age, the number and quality of the embryos, the couple's 
wishes, and by regulations in those countries where the number of embryos to be transferred is 
limited. Surplus good-quality embryos can be frozen and stored for later use. To reduce the 
number of multiple gestations, there is tendency toward transferring fewer embryos. In some 
countries, the transfer of only a single embryo is allowed. Although pregnancy rates per transfer 
are lower, following the transfer of 1 fresh and 1 cryopreserved embryo, the cumulative 
pregnancy rates are comparable to rates following the transfer of 2 embryos. Multiple 
pregnancies occur significantly less often. An efficient cryopreservation program needs to be in 
place, however, before one can comfortably offer elective single embryo transfer (37).  
This patient has oligo-anovulation; therefore, the assessment of her hormonal status is 
important. Most commonly, irregular ovarian activity has an endocrine etiology including 
thyroid disease, hyperprolactinemia, androgen excess, PCOS, premature ovarian failure. 
Transvaginal ultrasound will assess the morphology of the ovaries (ie, whether they are 
polycystic or not), myometrium, and endometrium. Serial ultrasound will document follicle 
growth and allows us to look at the changes in the endometrial lining (eg, thickness and type). 
Once the etiology of the irregular cycles is known, the appropriate treatment can be planned. 
Women with PCOS are at increased for impaired glucose tolerance (and diabetes), 
dylipidemia, and hypertension. Therefore, the baseline evaluation of these metabolic 
markers should be part of the work-up for this patient. 
Weight loss (life-style modification), CC, or insulin sensitizers could be recommended. At 
least half of women with PCOS are obese. Obesity is associated with insulin resistance that 
will further compromise ovarian activity. Weight loss and regular exercise are integral parts 
of their treatment. Weight loss is associated not only with improved ovarian function but 
also with lower risk for metabolic complications. CC and insulin sensitizers have both been 
shown to be effective for ovulation induction among women with oligo-ovulation. 
Adding an insulin sensitizer such as metformin would be the next step. A daily dose > 150 
mg of CC is not recommended, as higher doses compromise endometrial development, and 
pregnancy rates are very low. Insulin-sensitizing agents have been successfully used to treat 
infertile patients with PCOS. Metformin (1500-2000 mg daily) has been used most widely. 
With metformin, ovulation can be documented in about 50% to 60% of the cases. Metformin 
can be combined with CC in CC-resistant cases. Lower miscarriage rates and fewer cases of 
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gestational diabetes have been reported with metformin use. Metformin is a category B 
drug; no adverse effects have been reported with use during pregnancy. Once follicle 
growth is achieved, adding hCG can help the timing (intercourse or insemination). Without 
a mature follicle, however, hCG alone does not work. 
The patient's husband has a low sperm count. Therefore, IUI could improve this couple's 
chances for conception. IVF/ICSI would be recommended if IUI was not successful after 3 to 
6 attempts. 
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